ADMA Biologics Inc (NASDAQ:ADMA) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

Separately, Maxim Group set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a report on Wednesday, June 7th.

Shares of ADMA Biologics (NASDAQ ADMA) traded up 0.29% on Friday, reaching $3.46. 32,996 shares of the company were exchanged. ADMA Biologics has a 52 week low of $2.67 and a 52 week high of $7.70. The firm’s 50 day moving average price is $3.29 and its 200 day moving average price is $3.98. The stock’s market capitalization is $89.24 million.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.29. The business had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $3.52 million. ADMA Biologics had a negative net margin of 198.99% and a negative return on equity of 791.24%. Equities research analysts anticipate that ADMA Biologics will post ($1.94) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.